Bristol-Myers Squibb offers a 4%+ dividend yield backed by steady payout growth and strong cash flow, making it one of the more attractive income stocks in the healthcare sector.

Bristol Myers Squibb can navigate the dreaded patent cliff while maintaining modest dividend growth. Medtronic's strong, innovative business helps support its impressive dividend program. Considering ...

Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

In this podcast, Motley Fool contributor Rachel Warren talks with innovation consultant Lorraine Marchand, author of No Fear, No Failure, about the "five Cs" of innovation and how investors can ...

Prothena Corporation plc kept at Hold after mixed phase 2 results; key phase 3 readouts expected 2029. Click for this updated ...

When you get as many things going wrong as there are right now, you do not think about opportunity; you think about safety. I get that. We have the most uncertain of times in the Mideast after the U.S ...

The stock is roughly 25% below its late 2022 highs, which is part of the attraction. There's still some recovery opportunity ...

If you are wondering whether Bristol-Myers Squibb is offering good value right now, this article will walk through what the ...

IHE has an attractive mix of high-growth stocks and cheaply valued ones. Click here to find out why IHE stock is a Buy.

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain ...